Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2022 Update

Powered by

All the vital news, analysis, and commentary curated by our industry experts.

Covid 19 impact on Clinical Trials Market Analysis Report Overview

Since the first case of COVID-19 was diagnosed in Wuhan, China, in December 2019, COVID-19 cases rose rapidly across the globe. On March 11, 2020, World Health Organization (WHO) officially declared that COVID-19 is a pandemic.

Over 1,200 clinical trials worldwide have either been disrupted by COVID-19 due to suspended enrollment or delayed initiation or have been impacted by slow enrollment. Regulatory guidance has been issued for industry, investigators, and institutional review boards on conducting clinical trials during the COVID-19 pandemic, including suggested methods such as virtual visits, phone interviews, self-administration, and remote monitoring These suggestions could help trials that are being met with subject quarantine, travel limitations, clinical site closures, and interrupted supply chains.

The Coronavirus Disease 2019 (COVID-19) impact on clinical trials market research report gives an important update to the previous year with expert analysis on how COVID-19 is impacting clinical trials and the potential move toward decentralized clinical trials (DCTs).


The overall objective of the 2022 survey was to update and expand the understanding of the impact of COVID-19 on clinical trials and the industry’s view on adapting to DCTs. DCTs allow the collection of safety and efficacy data from study participants by using a range of digital technologies that require a minimum number of site visits. This can include telemedicine, wearable devices, eConsent, electronic clinical outcome assessments, and electronic health records.

The specific objectives of the 2022 survey were to:

  • Update to current perceptions as compared to this same report published in August 2021 and August 2020
  • Benchmark the companies’ primary concerns
  • Determine the impact of COVID-19 to date on clinical trials
  • Assess companies’ future plans to use DCTs
  • Track changes to clinical trial strategy and attitudes

Study Design

A total of 103 GlobalData Pharma clients and prospects from around the world participated in the seven-minute survey, which was fielded from June 29, 2022, to July 28, 2022. This report includes and is based on industry opinions on COVID-19’s impact on clinical trials and the use of DCTs.

Survey Respondent Mix

Survey Respondent Mix

Survey Respondent Mix

Survey Respondent Mix

For more insights on how COVID-19 is impacting the clinical trial sector, download a free report sample

Key Findings

Clinical trial disruption remains steady and slow enrollment continues to increase: The impact on clinical trial participants and the safety of patients were viewed as major and legitimate concerns. Currently, organizations are utilizing remote patient monitoring to mitigate clinical trial disruptions as a first step, but a plan to move toward DCTs will be the next step.

To know more about key findings, download a free report sample

Reasons to Buy

  • Understand companies’ primary concerns about the COVID-19 pandemic.
  • Determine the impact of COVID-19 to date on clinical trials.
  • Assess companies’ future plans to use decentralized clinical trials.
  • Track changes to clinical trial strategy and attitudes.

Table of Contents

Table of Contents (PowerPoint Deck)

1 Study Design

1.1 Background

1.2 Objectives and Design

1.3 Respondent Mix

1.4 Respondent Profiles

2 Key Findings

3 Primary Business and Clinical Trial Concerns

3.1 Primary Business Concerns

3.2 Primary Clinical Trial Concerns

3.3 Clinical Trial Disruptions

3.4 Addressing Clinical Trial Disruptions

4 Movement Toward Decentralized Trials

3.1 Therapy Areas Most Suited to Decentralized Trials

3.2 Pre-pandemic Decentralized Trials Use

3.3 Post-pandemic Decentralized Trials Use

3.4 Future Movement Toward Decentralized Clinical Trial Use

3.5 Cost Comparison

4 Challenges Facing Decentralized Trials

4.1 Biggest Changes

4.2 Biggest Considerations

4.3 Biggest Challenges

4.4 Risk Deviations

5 Summary of Key Findings

6 Appendix

7 Contact Us

Frequently asked questions

Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2022 Update thematic reports
Currency USD

Can be used by individual purchaser only


Can be shared globally by unlimited users within the purchasing corporation e.g. all employees of a single company

Undecided about purchasing this report?

Enquire Before Buying Request a Free Sample

Get in touch to find out about multi-purchase discounts
Tel +44 20 7947 2745

Every customer’s requirement is unique. With over 220,000 construction projects tracked, we can create a tailored dataset for you based on the types of projects you are looking for. Please get in touch with your specific requirements and we can send you a quote.

Sample Report

Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2022 Update was curated by the best experts in the industry and we are confident about its unique quality. However, we want you to make the most beneficial decision for your business, so we offer free sample pages to help you:

  • Assess the relevance of the report
  • Evaluate the quality of the report
  • Justify the cost

Download your copy of the sample report and make an informed decision about whether the full report will provide you with the insights and information you need.

Below is a sample report to understand what you are buying

See what our customers are saying

“The GlobalData platform is our go-to tool for intelligence services. GlobalData provides an easy way to access comprehensive intelligence data around multiple sectors, which essentially makes it a one-for-all intelligence platform, for tendering and approaching customers.

GlobalData is very customer orientated, with a high degree of personalised services, which benefits everyday use. The highly detailed project intelligence and forecast reports can be utilised across multiple departments and workflow scopes, from operational to strategic level, and often support strategic decisions. GlobalData Analytics and visualisation solutions has contributed positively when preparing management presentations and strategic papers.”

Business Intelligence & Marketing Manager, SAL Heavy Lift

“COVID-19 has caused significant interference to our business and the COVID-19 intelligence from GlobalData has helped us reach better decisions around strategy. These two highlights have helped enormously to understand the projections into the future concerning our business units, we also utilise the project database to source new projects for Liebherr-Werk to use as an additional source to pitch for new business.”

Market Analyst & Management, Liebherr-Werk

Your daily news has saved me a lot of time and keeps me up-to-date with what is happening in the market, I like that you almost always have a link to the source origin. We also use your market data in our Strategic Business Process to support our business decisions. By having everything in one place on the Intelligence Center it has saved me a lot of time versus looking on different sources, the alert function also helps with this.

Head of Key Accounts, Saab AB

Having used several other market research companies, I find that GlobalData manages to provide that ‘difficult-to-get’ market data that others can’t, as well as very diverse and complete consumer surveys.

Marketing Intelligence Manager, Portugal Foods

Our experience with GlobalData has been very good, from the platform itself to the people. I find that the analysts and the account team have a high level of customer focus and responsiveness and therefore I can always rely on. The platform is more holistic than other providers. It is convenient and almost like a one stop shop. The pricing suite is highly competitive and value for our organisation.

I like reports that inform new segments such as the analysis on generation Z, millennials, the impact of COVID 19 to our banking customers and their new channel habits. Secondly the specialist insight on affluent sector significantly increases our understanding about this group of customers. The combination of those give us depth and breadth of the evolving market.

I’m in the business of answering and helping people make decisions so with the intelligence center I can do that, effectively and efficiently. I can share quickly key insights that answer and satisfy our country stakeholders by giving them many quality studies and primary research about competitive landscape beyond the outlook of our bank. It helps me be seen as an advisory partner and that makes a big difference. A big benefit of our subscription is that no one holds the whole data and because it allows so many people, so many different parts of our organisation have access, it enables all teams to have the same level of knowledge and decision support.

Head of Customer Insight and Research, Standard Chartered

“I know that I can always rely on Globaldata’s work when I’m searching for the right consumer and market insights. I use Globaldata insights to understand the changing market & consumer landscape and help create better taste & wellbeing solutions for our customers in food, beverage and healthcare industries.

Globaldata has the right data and the reports are of very high quality compared to your competitors. Globaldata not only has overall market sizes & consumer insights on food & beverages but also provides insights at the ingredient & flavour level. That is key for B2B companies like Givaudan. This way we understand our customers’ business and also gain insight to our unique industry”

Head of Consumer Sensory Insights, Givaudan

GlobalData provides a great range of information and reports on various sectors that is highly relevant, timely, easy to access and utilise.  The reports and data dashboards help engagement with clients; they provide valuable industry and market insights that can enrich client conversations and can help in the shaping of value propositions. Moreover, using GlobalData products has helped increase my knowledge of the finance sector, the players within it, and the general threats and opportunities.

I find the consumer surveys that are carried out to be extremely beneficial and not something I have seen anywhere else. They provided an insightful view of why and which consumers take (or don’t) particular financial products. This can help shape conversations with clients to ensure they make the right strategic decisions for their business.

One of the challenges I have found is that data in the payments space is often piecemeal. With GD all of the data I need is in one place, but it also comes with additional market reports that provide useful extra context and information. Having the ability to set-up alerts on relevant movements in the industry, be it competitors or customers, and have them emailed directly to me, ensures I get early sight of industry activity and don’t have to search for news.

Senior Account Manager, TSYS
Go even deeper with GlobalData Intelligence Center

Every Company Report we produce is powered by the GlobalData Intelligence Center.

Subscribing to our intelligence platform means you can monitor developments at Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2022 Update in real time.

  • Access a live Coronavirus Disease 2019 (COVID-19) Impact on Clinical Trials, 2022 Update dashboard for 12 months, with up-to-the-minute insights.
  • Fuel your decision making with real-time deal coverage and media activity.
  • Turn insights on financials, deals, products and pipelines into powerful agents of commercial advantage.